abs331.txt	purpose	neoadjuvant	chemotherapy	followed	by	radical	cystectomy	(rc)	is	astandard	of	care	for	the	management	muscle-invasive	bladder	cancer	(mibc)	dose-dense	cisplatin-based	regimens	have	yielded	favorable	outcomes	compared	withstandard-dose		yet	optimal	regimen	remainsundefined	we	assessed	efficacy	and	tolerability	six	cycles	neoadjuvantdose-dense	gemcitabine	cisplatin	(ddgc)	in	patients	with	mibc	andmethods	this	prospective	multicenter	phase	ii	study	received	ddgc(gemcitabine	2	500	mg/m2	on	day	1	35	days	2)	every	2weeks	6	rc	primary	end	point	was	pathologicdownstaging	to	non-muscle-invasive	disease	(<	pt2n0)	who	did	notundergo	were	deemed	nonresponders	pretreatment	tumors	underwentnext-generation	sequencing	identify	predictors	chemosensitivity	resultsforty-nine	enrolled	from	three	institutions	pointwas	met	57%	46	evaluable	downstaged	<	pt2n0	pathologicresponse	correlated	improved	recurrence-free	survival	overall	nineteen	(39%)	required	toxicity-related	dose	modifications	sixty-sevenpercent	completed	all	planned	no	patient	failed	toundergo	as	a	result	chemotherapy-associated	toxicities	most	frequenttreatment-related	toxicity	anemia	(12%	grade	3)	presence	presumeddeleterious	dna	damage	response	(ddr)	gene	alteration	associated	withchemosensitivity	(positive	predictive	value	[89%])	adeleterious	ddr	has	experienced	recurrence	at	median	follow-upof	years	conclusion	ddgc	an	active	well-toleratedneoadjuvant	treatment	aputative	deleterious	tumor	tissue	stronglypredicted	durable	superior	long-termsurvival
